X

Drug Profile

Research programme: sensorineural hearing loss therapeutics - Astellas Pharma/Cell Mogrify

Latest Information Update: 12 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Astellas Pharma; Cell Mogrify
Class Gene therapies
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Sensorineural hearing loss

Most Recent Events

05 Jul 2022 Cell Mogrify and Astellas Pharma collaborate to develop in vivo reprogramming therapies for sensorineural hearing loss
05 Jul 2022 Early research in Sensorineural hearing loss in Japan (unspecified route)
05 Jul 2022 Early research in Sensorineural hearing loss in United Kingdom (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com